Seoul National University Bundang Hospital (SNUBH)
Liver cancer stage 3 treatment cost in South Korea typically includes essential diagnostics like an abdominal CT scan from AUD $833 to AUD $1,249. Primary surgical interventions or specialized therapies run from AUD $26,643 to AUD $56,895 depending on the complexity. Total expenses vary based on hospital tier and tumor size. Australians usually save 30–50% compared to private healthcare costs in Australia and the US. Most major treatment centres are located in Seoul and Incheon.
Typical Liver Cancer Stage 3 Treatment Costs in South Korea
Bookimed Expert Insight: Advanced stage 3 cases require high-volume centres for better outcomes. Asan Medical Center reports a 90% organ transplant success rate. This makes it ideal for complex surgical needs. Patients seeking rapid throughput benefit from digital systems at Seoul National University Bundang Hospital. It treats over 10,000 patients daily. For bloodless surgery, Korea University Anam Hospital uses specialized robotic techniques. These reduce the need for transfusions. JCI-accredited facilities like Severance Hospital ensure international safety standards for Australians.
| Republic of Korea | Thailand | Turkey | |
| Chemotherapy for breast cancer | from AUD $26,643 | from AUD $4,163 | from AUD $1,665 |
| Radiation therapy for colorectal cancer | - | from AUD $7,632 | from AUD $9,714 |
No hidden fees – just official clinic prices. Pay at the clinic for Liver cancer stage 3 treatment and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Liver cancer stage 3 treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Liver cancer stage 3 treatment journey.
Professor Lee Seok-gu is a leading liver transplant surgeon at Myongji Hospital. He has performed about 2,000 liver transplants. He achieved Korea’s first transfusion-free liver transplant. He performed hepatocyte transplantation in a one-month-old infant. He led the first clinical use of a bioartificial liver for acute liver failure. He also performed living-donor transplants in Egypt and trained teams in Vietnam.
He is Professor of Surgery at Myongji Hospital and former Director of the Organ Transplantation Center at Samsung Medical Center. He earned his MD and MSc from Seoul National University and his PhD from the Catholic University of Korea. He completed a fellowship at Boston Children’s Hospital/Harvard and transplant training at Johns Hopkins. He served as president of three national societies in transplantation and pediatric surgery. His honors include the Chong Kun Dang Award, the Pfizer Clinical Medicine Award, and the Astellas Investigator Award. He has 447 publications and 13 book chapters.
Immunotherapy for Stage 3 liver cancer is widely available in South Korea. Major Seoul centres use immune checkpoint inhibitors like atezolizumab and pembrolizumab for advanced hepatocellular carcinoma. These clinics often combine immunotherapy with targeted drugs. This approach improves outcomes when surgery is not an option.
Bookimed Expert Insight: Most patients focus on drug availability. However, South Korea's advantage lies in its high liver transplant success rates. Asan Medical Center reports a 98% success rate. For Stage 3 patients, experienced teams often bridge immunotherapy with other treatments. This helps manage the disease effectively.
Patient Consensus: Patients find immunotherapy effective for shrinking tumours. However, they note that out-of-pocket costs in South Korea can be high. They suggest confirming whether the cancer is hepatocellular carcinoma or cholangiocarcinoma. This should be done before starting treatment.
Key questions for Korean liver specialists should focus on surgical resection markers, living donor transplant eligibility, and advanced regional therapies. South Korea leads globally in liver transplant success rates. Patients prioritise multidisciplinary team reviews and the availability of immunotherapies like atezolizumab and bevacizumab for systemic control.
Bookimed Expert Insight: Many people assume Stage 3 limits surgical paths. However, Seoul National University Hospital and Asan Medical Center report over 1,000 liver transplants each. These centres often treat complex cases through 24/7 interpreter services and multidisciplinary teams. This high-volume experience allows Korean surgeons to perform procedures that may be considered too high-risk elsewhere.
Patient Consensus: Patients in the Republic of Korea recommend bringing all pathology records while preparing for repeated diagnostic scans. They note it is vital to clarify the treatment goal during initial consultations: local control or curative intent.
Standard care for Stage 3 liver cancer in South Korea involves aggressive locoregional control alongside systemic therapies. Specialists prioritise Transarterial Chemoembolisation (TACE) and Hepatic Arterial Infusion Chemotherapy (HAIC). These high-volume Seoul centres often use immunotherapy or living donor transplants for long-term survival in advanced cases.
Bookimed Expert Insight: Data shows South Korea leads in transplant volume. Asan Medical Center performs more organ transplants than any other domestic facility. While many countries follow strict Milan criteria, Korean specialists often use expanded criteria. This lets patients with larger Stage 3 tumours potentially qualify for living donor transplants after successful downstaging.
Patient Consensus: Patients note that major Seoul university hospitals often repeat diagnostic tests. This ensures precise staging before treatment starts. Practical wisdom suggests seeking a liver-specific multidisciplinary board. Korean protocols often combine chemotherapy, radiation, and immunotherapy for the best results.
International patients choose the Republic of Korea for Stage 3 liver cancer. They are drawn by superior success rates and surgical expertise. Major Seoul centres report a 98% liver transplant success rate. Specialists use living donor transplantation and robotic resections. These techniques allow them to treat complex cases that other regions may consider inoperable.
Bookimed Expert Insight: South Korea handles a massive volume of complex gastrointestinal cases. Seoul National University Bundang Hospital performs 32,550 operations annually. This high frequency allows surgeons to refine minimally invasive techniques. Many Western hospitals use open surgery for Stage 3 tumours. In contrast, Korean teams often use laparoscopic or robotic methods, which may reduce recovery time and scarring.
Patient Consensus: Patients value the speed of care in Seoul. They note that diagnostic tests and treatment plans often begin far quicker than in Western systems. The availability of English-speaking staff and personal coordinators helps patients navigate the intensive medical process comfortably.
Patients with Stage 3 liver cancer can access liver transplants in the Republic of Korea, primarily through living donor programs. Leading centres like Asan Medical Center report a 98% success rate. Specialists often use expanded criteria beyond standard guidelines to include advanced cases.
Bookimed Expert Insight: South Korea leads in living donor liver transplantation (LDLT). Asan Medical Center performs the highest number of transplants in Korea. Their 98% success rate stems from handling over 65,000 surgeries annually. This high volume allows surgeons to manage complex Stage 3 cases that other countries might reject.
Patient Consensus: Patients note that major Seoul centres require their own tests before confirming eligibility. Finding a matching living donor is essential. Metastatic cancer or spread beyond the liver usually rules out surgery in Korea.
TACE in South Korea treats Stage 3 liver cancer. It delivers chemotherapy directly to tumours via a microcatheter. Specialists use a superselective approach to target feeding vessels precisely. This method starves the cancer of blood and oxygen while sparing healthy liver tissue.
Bookimed Expert Insight: South Korea ranks 5th globally for medical requests on our platform. This is largely due to high-volume university centres. Asan Medical Center performs over 65,000 surgeries annually. It maintains a 98% liver transplant success rate. This level of extreme specialisation means Korean radiologists often handle complex Stage 3 cases. Other regions might deem them untreatable.
Patient Consensus: Patients note Korean hospitals are highly efficient. They appreciate the clear follow-up plans. They suggest requesting second opinions if tumour location makes TACE uncertain. Recovery usually involves 1 month of lower energy, but many report excellent long-term results.
SBRT and SIRT play a vital role in Korea as precise alternatives to surgery for Stage 3 liver cancer. These therapies achieve over 90% local control for inoperable cases. Leading Seoul hospitals use these techniques to manage portal vein invasion. They also bridge patients to transplantation.
Bookimed Expert Insight: While SBRT is the standard for localised control, Korea specialises in tomotherapy for complex Stage 3 cases. Gangnam Severance Hospital operates 2 tomotherapy devices. This technology allows doctors to adjust radiation beams in real-time. This is essential when liver tumours sit near sensitive organs.
Patient Consensus: Patients find radiation treatments straightforward with manageable fatigue. Many note that SIRT likely extended their lives. This happened even when surgery was not an option in Korea.